Your Trial Shows Up In AI. Now What?

Published 3 September 2026

Author(s): Ross Jackson

In part one of this series, I argued that clinical trial visibility is no longer simply a question of whether a study can be found online. As patients, physicians, site teams, sponsors, and CROs increasingly use AI tools to interpret clinical trial information, the more important question is whether AI-generated answers help the right stakeholder trust the trial, understand it, and take an appropriate next step.

That raises the follow-up question: If an AI visibility audit shows that a trial is being misunderstood, undersold, poorly sourced, or presented without a clear route forward, what should sponsors and their partners do about it?

The answer is not to game AI systems. In clinical research, that would be inappropriate and unlikely to work for long. The answer is to improve the information environment AI tools are drawing from — not only the sponsor’s trial page, but registry listings, patient-facing materials, site pages, CRO and recruitment partner content, referrer assets, publications, advocacy sources, and educational content that may shape how the study is found, interpreted, compared, and acted upon.